Table 2. Top 5-drug usage by patients with MS identified in the EMR.
| No | Disease modifying therapies | % |
|---|---|---|
| 1 | Interferon-beta | 43% |
| 2 | Glatiramer Acetate | 17% |
| 3 | Natalizumab | 7% |
| 4 | Fingolimod | 7% |
| 5 | Rituximab | 0.5% |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.